Head-to-head evidence
Alirocumab vs Evolocumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals
NCT01507831 · Phase 3 · completed
The study was large (2,341 participants), randomized, quadruple-blind, and placebo-controlled. Its primary clinical safety endpoint was reported, but the registry does not provide a statistical significance test for the comparison, so whether the primary endpoint was met cannot be determined.
Next expected readout: December 2026 · NCT07477704 (registry estimate)
Evolocumab · Repatha
Marketed by Amgen
NCT01516879 · Phase 3 · completed
The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome.
Next expected readout: November 2026 · NCT06496243 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Evolocumab's landscape